NCT02326311View on ClinicalTrials.gov

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

PHASE3CompletedINTERVENTIONAL

Enrollment

229

Participants

Timeline

Start Date

June 10, 2015

Primary Completion Date

December 31, 2023

Study Completion Date

May 29, 2024

Conditions

Leukemia, Chronic Myeloid

Interventions

DRUG

imatinib

Tyrosin kinase inhibitor

DRUG

nilotinib

Tyrosin kinase inhibitor

DRUG

dasatinib

Tyrosin kinase inhibitor

Trial Locations (1)

Unknown

Policlinico Universitario di Milano, Milan

All Listed Sponsors

lead

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

OTHER

NCT02326311 - Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response | Biotech Hunter | Biotech Hunter